Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fauvelle

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Annales Pharmaceutiques Francaises|April 2, 2002
[What can we do with cyclodextrins?]F Fauvelle, J C Debouzy
Annales Pharmaceutiques Francaises|January 1, 1994
[Demonstration of molecular combinations of alpha cyclodextrin (ACD) with dioctanoyl glycerol]F Fauvelle, M Idiri, J C Debouzy
Bollettino Chimico Farmaceutico|January 24, 1998
NMR study of per(3,6-anhydro) alpha cyclodextrin as a potential agent for the biological decontamination of leadJ C Debouzy, F Fauvelle, L Girault
Clinical Drug Investigation|August 13, 2016
Digoxin Toxicity : Evaluation in Clinical Practice with Pharmacokinetic CorrelationsK Lecointre, L Pisanté, F Fauvelle, et al.
Pathologie-Biologie|February 16, 2000
[Surgical antibiotic prophylaxis: point evaluation of practices]S Lefflot, A Lesquelen, P Blot, et al.
Journal of Clinical Apheresis|January 1, 1991
Zidovudine removal during plasma exchangeF Fauvelle, A Leon, O Petitjean, et al.
Therapie|September 1, 2000
Clinical pharmacokinetics during plasma exchangeF Fauvelle, O Petitjean, M Tod, et al.
Bollettino Chimico Farmaceutico|June 17, 2003
Hydrolytic properties of per (3,6-anhydro, 2-O-carboxymethyl) alpha cyclodextrin complexes of Ce (III) and Eu (III): application to soman (GD) degradationJ C Debouzy, A Gadelle, F Fauvelle, et al.
Fundamental & Clinical Pharmacology|October 13, 2000
Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitisL Belfayol-Pisanté, L Guillevin, M Tod, et al.
Annales Pharmaceutiques Francaises|January 1, 1995
[Interaction between 4-hydroxynonenane with membrane system. 1H, 31P, 2H NMR study]O Heintz, P Bossanne, F Fauvelle, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Annales Pharmaceutiques Francaises|April 2, 2002
[What can we do with cyclodextrins?]F Fauvelle, J C Debouzy
Annales Pharmaceutiques Francaises|January 1, 1994
[Demonstration of molecular combinations of alpha cyclodextrin (ACD) with dioctanoyl glycerol]F Fauvelle, M Idiri, J C Debouzy
Bollettino Chimico Farmaceutico|January 24, 1998
NMR study of per(3,6-anhydro) alpha cyclodextrin as a potential agent for the biological decontamination of leadJ C Debouzy, F Fauvelle, L Girault
Clinical Drug Investigation|August 13, 2016
Digoxin Toxicity : Evaluation in Clinical Practice with Pharmacokinetic CorrelationsK Lecointre, L Pisanté, F Fauvelle, et al.
Pathologie-Biologie|February 16, 2000
[Surgical antibiotic prophylaxis: point evaluation of practices]S Lefflot, A Lesquelen, P Blot, et al.
Journal of Clinical Apheresis|January 1, 1991
Zidovudine removal during plasma exchangeF Fauvelle, A Leon, O Petitjean, et al.
Therapie|September 1, 2000
Clinical pharmacokinetics during plasma exchangeF Fauvelle, O Petitjean, M Tod, et al.
Bollettino Chimico Farmaceutico|June 17, 2003
Hydrolytic properties of per (3,6-anhydro, 2-O-carboxymethyl) alpha cyclodextrin complexes of Ce (III) and Eu (III): application to soman (GD) degradationJ C Debouzy, A Gadelle, F Fauvelle, et al.
Fundamental & Clinical Pharmacology|October 13, 2000
Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitisL Belfayol-Pisanté, L Guillevin, M Tod, et al.
Annales Pharmaceutiques Francaises|January 1, 1995
[Interaction between 4-hydroxynonenane with membrane system. 1H, 31P, 2H NMR study]O Heintz, P Bossanne, F Fauvelle, et al.
Pageof 6